WHO WE ARE
CELZ has developed/acquired a robust intellectual property (IP) portfolio related to the utilization of stem cells to improve patient lives in the areas of immunology, urology, neurology, and orthopedics.
This IP portfolio positions us at the forefront of the regenerative medicine industry (set to grow to $79Bn 2026). We plan to commercialize these products on our own and in collaboration with strategic partners.
Chief Executive Officer
Chief Financial Officer
Chief Commercial Officer
Director of Clinical Development
Bruce S. Urdang
Camillo Ricordi, MD
Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM). Director of the Diabetes Research Institute and the Cell Transplant Center
Boris Reznik, A.S., M.S., Ph.D.
Chairman of Venvalo Group. 40+ years investing in and building multiple technology-based companies
Timothy Henry MD
Director of Cardiology, Christ Hospital, Cincinnati, OH. Dr. Henry’s experience also includes Director of Research at Minneapolis Heart Institute Foundation
Santosh Kesari, MD, PhD
Director, Neuro-oncology; Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute
We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.
For inquiries, please contact the company: TimW@CreativeMedicalTechnology.com